Evidence map›Paper›PMID 41928426›Full record

ArticleJournal of cellular and molecular medicine2026

Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma.

Domenica Ronchetti, Valentina Traini, Ilaria Silvestris, Giuseppina Fabbiano, Andrea Devecchi, Federica Torricelli, Noemi Puccio, Ilaria Craparotta, Marco Bolis, Roberto Piva and 5 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Domenica RonchettiDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Valentina TrainiDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Ilaria SilvestrisDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Giuseppina FabbianoHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Andrea DevecchiDepartment of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Federica TorricelliLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Noemi PuccioLaboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Ilaria CraparottaComputational Oncology Unit, Experimental Oncology Department, Mario Negri IRCCS, Milan, Italy.
Marco BolisComputational Oncology Unit, Experimental Oncology Department, Mario Negri IRCCS, Milan, Italy.
Roberto PivaDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Antonino NeriScientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Luca AgnelliDepartment of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Francesco PassamontiDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Niccolò BolliDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Elisa TaianaHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Funding

Associazione Italiana per la Ricerca sul Cancro IG 2020-ID.24365Associazione Italiana per la Ricerca sul Cancro IG25739Associazione Italiana per la Ricerca sul Cancro MFAG 2022-ID.27606European Union's Horizon 2020 817997Italian Ministry of Health, current research IRCCS
6 · The paper itself

Abstract

The lncRNA NEAT1 is overexpressed in multiple myeloma (MM) plasma cells and plays a key role in MM pathogenesis. NEAT1 is involved in ceRNA network in several cancers; however, data in MM are virtually absent. This study identified a NEAT1-driven ceRNA network involving 96 miRNAs and 40 target genes, selected as concurrently downregulated in NEAT1-KD AMO1 cells and upregulated in NEAT1-overexpressing AMO1 cells (AMO1-OVX). The co-expression of NEAT1 and the targets was validated in MM patients (GSE116294, GSE13591, GSE6477, CoMMpass), and in NEAT1-KD NCI-H929, LP1, and KMS27 cell lines, showing for all targets a consistent downregulation, resembling that of NEAT1. The functional implication of the ceRNA network was explored by functional enrichment analyses of the 40 targets, identifying 78 significant gene sets, 17 of which were found significantly enriched by GSEA analysis in at least one experimental condition among NEAT1-KD LP1, NCI-H929, and KMS27 cells, AMO1-OVX cells, or the extreme quartiles of NEAT1 expression in the CoMMpass dataset. Noteworthy, the cell cycle gene set was validated in 5 out of 6 conditions tested, suggesting that in MM the impact of NEAT1 upregulation on the cell cycle, experimentally demonstrated in our earlier publications, may be attributable, at least partially, to ceRNA mechanisms.

Indexed as

Gene Expression Regulation, NeoplasticGene Regulatory NetworksMultiple MyelomaRNA, Competitive EndogenousRNA, Long NoncodingCell Line, TumorGene Expression ProfilingHumansMicroRNAsMicroRNAsNEAT1 long non-coding RNA, humanRNA, Competitive EndogenousRNA, Long NoncodingceRNA networkmultiple myelomaNEAT1

Identifiers

PMID41928426
PMCPMC13051828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.